Literature DB >> 20882125

The Art of Managing Conversions between Antiepileptic Drugs: Maximizing Patient Tolerability and Quality of Life.

Erik K St Louis1.   

Abstract

Conversion between anti-epilectic drugs (AEDs) is frequently necessary in epilepsy care, exposing patients to a risk of incurring adverse effects and reduced quality of life. Little practical guidance is available to practitioners to guide conversions between AED monotherapies, or in adding a new adjunctive AED into a polytherapy regimen. This article reviews the impact of adverse effects of AEDs on quality of life in epilepsy patients, then reviews several important patient-related factors such as age, gender, medical and psychiatric co-morbidities, and co-medications that must be considered when selecting AEDs and ensuring tolerable and safe AED conversions. Practical strategies for transitional polytherapy AED conversion are then considered in different commonly encountered clinical scenarios in newly diagnosed and refractory epilepsy care, including inadequate seizure control, intolerable adverse effects, or idiosyncratic safety hazards. Successful conversion between AEDs requires regular monitoring for patient-reported adverse effects and appropriately reactive adjustment of AED therapy to maximize patient quality of life.

Year:  2010        PMID: 20882125      PMCID: PMC2946260          DOI: 10.3390/ph3092956

Source DB:  PubMed          Journal:  Pharmaceuticals (Basel)        ISSN: 1424-8247


  66 in total

Review 1.  Monotherapy trials: presurgical studies.

Authors:  G Pledger
Journal:  Epilepsy Res       Date:  2001-05       Impact factor: 3.045

2.  Rapid initiation of gabapentin: a randomized, controlled trial.

Authors:  R S Fisher; R C Sachdeo; J Pellock; P E Penovich; L Magnus; P Bernstein
Journal:  Neurology       Date:  2001-03-27       Impact factor: 9.910

3.  Effectiveness of first antiepileptic drug.

Authors:  P Kwan; M J Brodie
Journal:  Epilepsia       Date:  2001-10       Impact factor: 5.864

Review 4.  The importance of drug interactions in epilepsy therapy.

Authors:  Philip N Patsalos; Walter Fröscher; Francesco Pisani; Clementina M van Rijn
Journal:  Epilepsia       Date:  2002-04       Impact factor: 5.864

Review 5.  Assessment of adverse events and quality of life in epilepsy: design of a new community-based trial.

Authors:  Michael Privitera; David M Ficker
Journal:  Epilepsy Behav       Date:  2004-12       Impact factor: 2.937

Review 6.  Metabolic consequences of antiepileptic drugs.

Authors:  Scott Mintzer
Journal:  Curr Opin Neurol       Date:  2010-04       Impact factor: 5.710

7.  Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein.

Authors:  Scott Mintzer; Christopher T Skidmore; Caitlin J Abidin; Megan C Morales; Inna Chervoneva; David M Capuzzi; Michael R Sperling
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

8.  Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin.

Authors:  R Gilad; N Izkovitz; R Dabby; A Rapoport; M Sadeh; B Weller; Y Lampl
Journal:  Acta Neurol Scand       Date:  2008-11       Impact factor: 3.209

9.  Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial.

Authors:  F G Gilliam; A J Fessler; G Baker; V Vahle; J Carter; H Attarian
Journal:  Neurology       Date:  2004-01-13       Impact factor: 9.910

10.  Concerns with AED conversion: comparison of patient and physician perspectives.

Authors:  Brien J Smith; Erik K St Louis; John M Stern; Chad Green; Thomas Bramley
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

View more
  2 in total

1.  Seizure treatment in transplant patients.

Authors:  Paul W Shepard; Erik K St Louis
Journal:  Curr Treat Options Neurol       Date:  2012-08       Impact factor: 3.598

2.  Impact of the implementation of the AAN epilepsy quality measures on the medical records in a university hospital.

Authors:  J Miguel Cisneros-Franco; Marco A Díaz-Torres; Juan B Rodríguez-Castañeda; Alejandro Martínez-Silva; Mildred A Gutierrez-Herrera; Daniel San-Juan
Journal:  BMC Neurol       Date:  2013-08-28       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.